Long-term study of Chinese adults with fatty liver disease
Follows Chinese adults with fatty liver disease over 10 years through observation.
Plain-language title generated from the registry record
Registry title: Longitudinal Observational Study Of Chinese With NAFLD/NASH
Key facts
- Where
- Hong Kong, Hong KongSee the site
Where in Hong Kong
- Humanity and Health Medical CentreHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Humanity and Health Research Centre
- Trial code
- NCT03151473
- Record updated
- 29 July 2026
- Original description
This is a 10-year, longitudinal, observational study of patients with NAFLD/NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, the biospecimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.Read full original descriptionShow less
Prospective Cohort Assessing The Prevalence And Progress Of Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) In Chinese Subjects
This is a 10-year, longitudinal, observational study of patients with NAFLD/NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, the biospecimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.
Inclusion: Males or females aged 18 and older; Adults being managed or treated for NAFL or NASH; Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent.
Exclusion: Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, among others, and conditions associated with microvesicular steatosis; Diagnosis of chronic inflammatory disease (i.e. inflammatory bowel disease, rheumatoid arthritis, inflammatory lung disease, severe infectious diseases), other than NAFL/NASH; Incompetent to understand and/or sign the informed consent; Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for female; Diagnosis of liver cirrhosis and/or hepatocellular carcinoma.